The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Improving early lung cancer detection with liquid biopsy TCR sequencing
Luis Montuenga, PhD, University of Navarra, Pamplona, Spain, discusses the use of T-cell receptor (TCR) sequencing in liquid biopsy to improve early lung cancer detection. The study analyzed circulating TCR repertoires from patients with lung cancer. By identifying 197 cancer-associated TCR functional units (RFUs) and integrating them into a predictive model, the approach significantly enhanced sensitivity when combined with existing circulating tumor DNA (ctDNA) and protein biomarkers. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
